TRITON2: A Multicenter Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Brief description of study
If you have been diagnosed with prostate cancer, that is found to be metastatic castration-resistant, which is a disease state characterized by resistance to standard androgen deprivation therapies (ADT) and if your cancer has one of a specific set of genetic mutations in DNA damage repair (homologous recombination deficiency) you may qualify to participate in this study. The main goal of this phase II study is to evaluate the safety, effectiveness of the drug, rucaparib for the treatment of prostate cancer and what effects, good and/or bad, rucaparib has on people with metastatic castration-resistant prostate cancer. In addition, we would like to study blood sample to understand how much rucaparib is in your blood over time, which is known as pharmacokinetic (PK) testing.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
